Latest news

• Axovant licenses another gene therapy as new strategy beds in

  The push into gene therapy comes after Axovant was forced to abandon its former lead candidate intepirdine for Alzheimer’s disease after it failed late-stage testing, which led to the

• Axovant bets on gene therapy with $842.5m Oxford BioMedica deal

  The addition of OXB-102 is the first pipeline-building deal for Axovant since it gave up on lead candidate intepirdine in February, and a whole new area of focus for ... tisagenleucel). Axovant CEO Pavan Cheruvu, who took the helm of the company after

• Another Alzheimer's bust as Merck & Co stops verubecestat study

  Axovant Sciences dropped its 5-HT6 receptor antagonist intepirdine.

• After Axovant shock, Roivant pens diabetes deal with Poxel

  Hung’s resignation hasn’t come out of the blue, given Axovant’s 5-HT6 receptor antagonist intepirdine has fallen short of the mark in a series of clinical tests over

• Axovant joins ever-growing Alzheimer’s failure club

  5-HT6 inhibitor Intepirdine followsin the footsteps of Lundbeck's idalopirdine. Axovant’s phase III trial of Alzheimer’s disease (AD) candidate intepirdine has ended in failure, an outcome that ... Intepirdine - a serotonin 5-HT6 inhibitor - failed